Atmo Biosciences Expands U.S. Operations for Gastrointestinal Diagnostic Tech
Atmo Biosciences 擴展其美國業務以推動胃腸道診斷技術發展
Atmo Biosciences, an Australian health innovator, is successfully bringing its groundbreaking diagnostic technology to the United States.
Atmo Biosciences，一家澳洲的健康創新企業，正成功地將其突破性的診斷技術引入美國。
In 2025, the company received FDA clearance for its ingestible gas-sensing capsule, a device designed to revolutionize how clinicians diagnose gastrointestinal motility disorders like gastroparesis.
2025年，該公司獲得了美國食品藥物管理局（FDA）對其可攝入氣體感測膠囊的許可。
This pill-sized capsule travels through the digestive tract, wirelessly measuring gases to provide objective, non-invasive data on gut transit times.
這款裝置旨在徹底改變臨床醫師診斷胃輕癱等胃腸道動力障礙的方式。
Unlike traditional tests that involve radiation, this method allows patients to maintain their daily routine during the evaluation.
這種藥丸大小的膠囊在消化道中移動，透過無線方式測量氣體，為腸道運輸時間提供客觀且非侵入性的數據。
Following a successful commercial launch in the Northeast, the company has seen impressive 700% revenue growth by April 2026.
與傳統涉及輻射的檢查不同，這種方法讓病患在評估過程中能維持日常生活。
Based in San Diego, the company is now focused on broad distribution within hospitals and specialty clinics.
為了支持這一動能，Atmo擴展了其美國領導團隊，任命資深業內人士Martin Reid為銷售資深副總裁，以推動全國範圍的擴張。
While currently focused on motility, Atmo is also investigating the capsule’s future potential in diagnosing conditions like IBS and SIBO.
該公司總部位於聖地牙哥，目前專注於在醫院和專科診所進行廣泛分銷。
With proven clinical validation and strong physician adoption, Atmo Biosciences is rapidly establishing itself as a key player in the U.S. medical device market.
儘管目前聚焦於動力問題，Atmo也在研究該膠囊未來在診斷腸躁症(IBS)和小腸細菌過度生長(SIBO)等疾病上的潛力。
